Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-606-6491
Fax+1 206-606-2042
Dr. Coveler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a medical oncologist who treats cancers of the gastrointestinal system and also the director of the Pancreatic Cancer Specialty Clinic at Seattle Cancer Care Alliance. My goal is to be an educator for my patients and to guide them through the unknown and advocate for their choices when it comes to their care. I find this provides my patients with optimal care and permits them to create a plan that empowers them to confront the disease on their own terms. My clinical areas of expertise include gastrointestinal oncology, clinical immunotherapy, and early phase clinical trials.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2007 - 2010
Baylor College of MedicineInternship, Internal Medicine, 2002 - 2003
Northwestern University The Feinberg School of MedicineClass of 2002
Northwestern UniversityBachelor of Arts, Biology, Magna Cum Laude, 1995 - 1998
Certifications & Licensure
FL State Medical License 2021 - Present
WA State Medical License 2005 - 2026
ID State Medical License 2022 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Perioperative Therapy for Resectable Pancreatic Cancer Start of enrollment: 2008 Jan 01
- Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- Exercise Guidelines in Pancreatic Cancer Based on the Dietz Model.Philip J Chang, Andrew E Hendifar, Gillian Gresham, An Ngo-Huang, Paul E Oberstein
Cancers. 2025-02-13 - A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer.William R Gwin 3rd, Lupe G Salazar, James Y Dai, Doreen Higgins, Andrew L Coveler
Vaccines. 2025-01-24 - The power of personas: Exploring an innovative model for understanding stakeholder perspectives in an oncology learning health network.Dylan J Cooper, Jessie Karten, Sarah E Hoffe, Daniel A King, Matthew Weiss
Learning Health Systems. 2025-01-01
Journal Articles
- KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
Press Mentions
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic CancerFebruary 25th, 2025- Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023
- NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022September 12th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
